Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03151707 · ClinicalTrials.gov registry record · Phase 4
The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics
A Phase 4 study, sponsored by Mclean Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03151707 is a Phase 4 study that was terminated before completion, run by Mclean Hospital. The registered enrollment target is 11 participants.
The verdict
NCT03151707, a Phase 4 study, was terminated before completion, sponsored by Mclean Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain NAD+/NADH ratio and bioenergetics functions in healthy individuals using phosphorus magnetic resonance spectroscopy (31P MRS) imaging. The secondary aims are to investigate the change in brain PCr/ATP and creatine kinase enzyme rate after NR use. In addition, NAD+/NADH ratio, PCr/ATP and CK enzyme rate will be measured in the calf muscle, as secondary outcome measures.
Interventions
- DRUG Nicotinamide Riboside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03151707
The ClinicalTrials.gov registry entry for NCT03151707 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nicotinamide Riboside is the first listed.
NCT03151707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03151707 about?
NCT03151707 is a clinical study titled "The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics". The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain NAD+/NADH ratio and bioenergetics functions in healthy individuals using phosphorus magnetic resonance spectroscopy (31P MRS) imaging. The secondary aims are to investigate th...
What is the current status of trial NCT03151707?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2017-10-01. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT03151707?
The interventions under investigation include: Nicotinamide Riboside (DRUG).
Who is sponsoring clinical trial NCT03151707?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.